FindMyRecallSubscribe
Class I: serious health riskTerminated

Amneal Pharmaceuticals of New York Lorazepam Oral Concentrate Recall

Lorazepam Oral Concentrate, USP, 2 mg/mL, 30 mL bottle, Rx only, Manufactured by: Amnea…

Amneal Pharmaceuticals of New York, LLC · Brookhaven, NY

Risk level
Class I
Reported by FDA
Dec 27, 2017
Recall ID
D-0120-2018
Check your lot numberHow we source this data

Summary

Amneal Pharmaceuticals of New York recalled Lorazepam Oral Concentrate starting Aug 3, 2017. The FDA classified it as Class I (serious health risk) and published enforcement report D-0120-2018 on Dec 27, 2017. Reason: Defective Delivery System: the dropper measurement markings may be reversed, shifted or missing. Status: Terminated.

Why it was recalled

Defective Delivery System: the dropper measurement markings may be reversed, shifted or missing.

Product description

Lorazepam Oral Concentrate, USP, 2 mg/mL, 30 mL bottle, Rx only, Manufactured by: Amneal Pharmaceuticals Branchburg, NJ 08876. Distributed by: Amneal Pharmaceuticals, Glasgow, KY 42141. NDC 65162-687-84

Lot numbers, UPCs & expiration codes

Lot 06876016A, 06876017A, 06876018A, Exp 08/2018; 06876019A, 06876020A, 06876021A, 06876022A, Exp 09/2018; 06876023A, Exp 11/2018; 06876024A, 06876025A, Exp 12/2018; 06877001A, 06877002A, Exp 02/2019; 06877003A, Exp 03/2019.

Where it was sold

Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0120-2018
Classification
Class I
Status
Terminated
Recall initiated
Aug 3, 2017
FDA report date
Dec 27, 2017
Quantity
136376 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Amneal Pharmaceuticals of New York, LLC

Original FDA data

Every field from FDA enforcement report D-0120-2018, exactly as published.

Show all FDA fields
City
Brookhaven
State
NY
Status
Terminated
Country
United States
Event ID
77898
Address
50 Horseblock Rd
Code information
Lot 06876016A, 06876017A, 06876018A, Exp 08/2018; 06876019A, 06876020A, 06876021A, 06876022A, Exp 09/2018; 06876023A, Exp 11/2018; 06876024A, 06876025A, Exp 12/2018; 06877001A, 06877002A, Exp 02/2019; 06877003A, Exp 03/2019.
Postal code
11719-9509
Report date
Dec 27, 2017
Product type
Drugs
Recall number
D-0120-2018
Classification
Class I
Recalling firm
Amneal Pharmaceuticals of New York, LLC
Product quantity
136376 bottles
Termination date
Sep 7, 2022
Reason for recall
Defective Delivery System: the dropper measurement markings may be reversed, shifted or missing.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Lorazepam Oral Concentrate, USP, 2 mg/mL, 30 mL bottle, Rx only, Manufactured by: Amneal Pharmaceuticals Branchburg, NJ 08876. Distributed by: Amneal Pharmaceuticals, Glasgow, KY 42141. NDC 65162-687-84
Distribution pattern
Nationwide
Recall initiation date
Aug 3, 2017
Initial firm notification
Letter
Center classification date
Dec 20, 2017

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0120-2018, published Dec 27, 2017. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls